Trials / Completed
CompletedNCT04957914
A Study of LY3209590 on Low Blood Sugar in Participants With Type 2 Diabetes Mellitus
Effects of LY3209590 on Frequency and Severity of Hypoglycaemia Under Conditions of Increased Hypoglycaemic Risk Compared to Insulin Glargine in Participants With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the effect of study drug known as LY3209590 compared to insulin glargine administered in participants with type 2 diabetes mellitus (T2DM). Side effects and tolerability will be documented. The study will last almost six months and 21 visits for each participant including screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Insulin Glargine | Administered SC |
| DRUG | LY3209590 | Administered SC |
Timeline
- Start date
- 2021-07-14
- Primary completion
- 2022-10-17
- Completion
- 2022-10-17
- First posted
- 2021-07-12
- Last updated
- 2022-11-16
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04957914. Inclusion in this directory is not an endorsement.